Comparison of Pioglitazone and Empagliflozin for Treating Diabetes in Adults with Chronic or Acute Pancreatitis

What this Trial Is About

Researchers are evaluating the effectiveness of pioglitazone PIO versus empagliflozin EMPA to improve blood sugar control in adults aged 18 to 80 years who have diabetes associated with chronic pancreatitis CP, recurrent acute pancreatitis RAP, or acute pancreatitis AP. The study aims to better understand how these two medications affect the bodys response to mixed meals and overall glucose regulation in these conditions. Participants will be randomly assigned to receive either pioglitazone or empagliflozin. Pioglitazone will be given as a 30 mg tablet once daily in the morning for 12 weeks, with the dose potentially increased to 45 mg based on blood sugar levels. Empagliflozin will start at 10 mg once daily in the morning for 12 weeks, with a possible increase to 25 mg depending on blood sugar control. This dose escalation will occur at 12 weeks and continue until 24 weeks of treatment. During the 24-week study, participants will undergo various assessments including measurements of hemoglobin A1c HbA1c, glucose, insulin, C-peptide, and glucagon levels. Researchers will also monitor body composition, cholesterol, inflammatory markers, body weight, blood pressure, and patient-reported health outcomes. Participants will perform blood glucose and ketone testing using study-provided meters. Safety and treatment effects will be closely observed throughout the study period.

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus